纳洛酮治疗慢阻肺并Ⅱ型呼吸衰竭的疗效及安全性评价

摘要

Objective To explore the clinical efficacy and drug safety evaluation of application of naloxone in treating chronic ob-structive pulmonary disease and respiratory failure. Methods 72 cases of COPD patients with type II respiratory failure as the ob-ject of study were selected in our hospital from January,2011 to October,2014, two groups of patients were given conventional treatment. On the basis of the observation group received naloxone, blood gas before and after treatment in two groups were com-pared by analysis of four indicators of changes, clinical effect and adverse reaction incidence rate. Results There were no signifi-cant index analysis of pH, PaO2, PaCO2 and SaO2 difference between the two groups before treatment, blood gas (P>0.05), two groups of blood gas analysis after treatment indicators have improved, but the observation group indicators were significantly better than the control group (P<0.05). Effective rate of treatment in the control group was 75.5%, the effective rate of treatment in obser-vation group was 94.4%, the observation group was significantly higher than the control group, the difference has statistical signifi-cance (P<0.05). Two groups of patients have nausea, vomiting and other phenomena, no adverse reaction of arrhythmia, twitch. The incidence of adverse reaction in the control group was 11.1% and the observation group was16.7%, no significant difference be-tween two groups (P>0.05). Conclusion Naloxone in the treatment of COPD and type II respiratory failure have clinical curative effect, which can effectively relieve respiratory inhibition, promote ventilation, improve hypoxia and CO2 retention, and high safety, can be widely applied in clinical practice.%目的：对应用纳洛酮治疗慢阻肺并Ⅱ型呼吸衰竭的临床疗效与用药安全性进行评价。方法随机选取2011年1月-2014年10月该院收治的72例慢阻肺并II型呼吸衰竭患者为研究对象，根据随机数字表法分为两组。两组患者均给予常规治疗，观察组在此基础上给予纳洛酮，比较两组患者治疗前后的血气分析四项指标变化、临床疗效及不良反应发生率。结果两组治疗前血气分析指标pH、PaO2、PaCO2及SaO2差异无统计学意义(P>0.05)，治疗后两组血气分析指标均有所好转，但观察组各项指标均显著优于对照组(P<0.05)。对照组治疗有效率为75.5%，观察组治疗有效率为94.4%，组间比较观察组明显高于对照组，差异有统计学意义(P<0.05)。两组均有患者出现恶心、呕吐等现象，无心律失常、抽搐等不良反应。其中对照组不良反应发生率为11.1%，观察组为16.7%，组间比较差异无统计学意义(P>0.05)。结论纳洛酮在治疗慢阻肺并Ⅱ型呼吸衰竭中临床疗效显著，能有效解除呼吸抑制，促进通气，改善机体缺氧与CO2潴留，且安全性高，可在临床上进行推广应用。